Defence Therapeutics (TSE:DTC) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Defence Therapeutics, a Canadian biotech firm, is advancing cancer treatment by developing a novel targeted Radio-Immuno-Conjugate (RIC) in partnership with the multinational nuclear company Orano. Their innovative RIC, which leverages Defence’s proprietary Accum technology, aims to deliver radioactivity directly to cancer cells while minimizing damage to healthy tissue. This cutting-edge approach could revolutionize cancer therapy by utilizing Auger electron emitters, previously unused due to their limitations.
For further insights into TSE:DTC stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money